Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 9/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173102 | 0.91 | NR1I2 (0.42) | NR1I2 | |
| SCHEMBL137809 | 0.88 | NR1I2 (0.48) | NR1I2 | |
| SCHEMBL102054 | 0.88 | NR1I2 (0.48) | NR1I2 | |
| SCHEMBL12446819 | 0.87 | RAF1 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL173183 | 0.85 | NR1I2 (0.36) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL2106257 | 0.85 | — | — | |
| SCHEMBL2106259 | 0.85 | — | — | |
| SCHEMBL173100 | 0.84 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12945313 | 0.84 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12949453 | 0.84 | RAF1 (0.38) | NR1I2RAF1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | disclosed |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-11-29 | — | — | US | disclosed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | disclosed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885RAF1 1444/4885MAPK14 3447/4885 |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885RAF1 1444/4885MAPK14 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.